Compare Novartis AG (NVS) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Phillips 66 — how do they compare? Novartis AG trades at $138.17 (market cap $262.64B), while Phillips 66 trades at $261.97 (market cap $103.40B). The key difference: Novartis AG is far larger — about 2.5× Phillips 66's market cap, and Novartis AG pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| NVS | PSX | |
|---|---|---|
Market Cap | $262.64B | $103.40B |
Sector | Health | Energy |
52-Week High | $168.62 | $260.78 |
52-Week Low | $121.80 | $126.76 |
Enterprise Value | $303.97B | $119.87B |
Dividend Yield | 3.44% | 1.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
PSX trades at $259.14, up 1.59% today and near its 52-week high, supported by bullish technical signals and strong earnings beats in recent quarters. The stock shows robust profitability with a 24.02% ROE and attractive valuation metrics, including a P/E of 14.79. Recent news highlights momentum from high gas prices and refining efficiency gains, with a dividend of $1.27 payable in September 2026.
Outlook remains positive due to earnings momentum and sector tailwinds, but risks include volatile energy markets and declining revenue trends. Analysts are predominantly bullish with a $242.45 consensus target, though the current price exceeds this, suggesting near-term caution. Institutional buying and stable cash flow growth support long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
